1 |
Seman LJ, DeLuca C, Jenner JL, Cupples LA, McNamara JR, Wilson PW, et al. Lipoprotein (a)-cholesterol and coronary heart disease in the framingham heart study. Clin Chem. 1999;45:1039-1046. https://doi.org/10.1093/clinchem/45.7.1039
DOI
|
2 |
Sahebkar A, Serban M, Penson P, Gurban C, Ursoniu S, Toth P, et al. Lipid and blood pressure meta-analysis collaboration (LBPMC) group. the effects of tamoxifen on plasma lipoprotein (a) concentrations: systematic review and meta-analysis. Drugs. 2017;77:1187-1197. https://doi.org/10.1007/s40265-017-0767-4
DOI
|
3 |
Wang J, Hu B, Kong L, Cai H, Zhang C. Native, oxidized lipoprotein (a) and lipoprotein (a) immune complex in patients with active and inactive rheumatoid arthritis: plasma concentrations and relationship to inflammation. Clin Chim Acta. 2008;390:67-71. https://doi.org/10.1016/j.cca.2007.12.015
DOI
|
4 |
Ross R. The pathogenesis of atherosclerosis-an update. N Engl J Med. 1986;314:488-500. https://doi.org/10.1056/NEJM198602203140806
DOI
|
5 |
Nordestgaard B, Chapman M, Ray K, Boren J, Andreotti F, Watts G, et al. For the european athersclerosis society consensus panel: lipoprotein(a) as a cardiovascular risk factor; current status. Eur Heart J. 2014;35:1683-1693. https://doi.org/10.1093/eurheartj/ehq386
DOI
|
6 |
O'Donoghue ML, Fazio S, Giugliano RP, Stroes ES, Kanevsky E, Gouni-Berthold I, et al. Lipoprotein (a), PCSK9 inhibition, and cardiovascular risk: insights from the FOURIER trial. Circulation. 2019;139:1483-1492. https://doi.org/10.1161/CIRCULATIONAHA.118.037184
DOI
|
7 |
Zhang W, Speiser JL, Ye F, Tsai MY, Cainzos-Achirica M, Nasir K, et al. High-sensitivity C-reactive protein modifies the cardiovascular risk of lipoprotein(a) multi-ethnic study of atherosclerosis. J Am Coll Cardiol. 2021;78:1083-1094. https://doi.org/10.1016/j.jacc.2021.07.016
DOI
|
8 |
Ravnskov U, Diamond DM, Hama R, Hamazaki T, Hammarskjold B, Hynes N, et al. Lack of an association or an inverse association between low-density-lipoprotein cholesterol and mortality in the elderly: a systematic review. Br Med J. 2016;6:e010401. https://doi.org/10.1136/bmjopen-2015-010401
DOI
|
9 |
Johannesen CDL, Mortensen MB, Langsted A, Nordestgaard BG. Apolipoprotein B and non-HDL cholesterol better reflect residual risk than LDL cholesterol in statin-treated patients. J Am Coll Cardiol. 2021;77:1439-1450. https://doi.org/10.1016/j.jacc.2021.01.027
DOI
|
10 |
de Isla LP, Masana L, Argueso R, Campuzano R, Egocheaga I, Escobar C, et al. Comments on the 2019 ESC/EAS guidelines for the management of dyslipidemias. Rev Esp Cardiol (Engl Ed). 2020;73:348-353. https://doi.org/10.1016/j.rec.2019.11.019
DOI
|
11 |
Ariyo AA, Thach C, Tracy R. Lp (a) lipoprotein, vascular disease, and mortality in the elderly. N Engl J Med. 2003;349:2108-2115. https://doi.org/10.1056/NEJMoa001066
DOI
|
12 |
Romagnuolo R, Scipione CA, Boffa MB, Marcovina SM, Seidah NG, Koschinsky ML. Lipoprotein (a) catabolism is regulated by proprotein convertase subtilisin/kexin type 9 through the low density lipoprotein receptor. J Biol Chem. 2015;290:11649-11662. https://doi.org/10.1074/jbc.M114.611988
DOI
|
13 |
Knight BL, Perombelon YN, Soutar AK, Wade DP, Seed M. Catabolism of lipoprotein (a) in familial hypercholesterolaemic subjects. Atherosclerosis. 1991;87:227-237. https://doi.org/10.1016/0021-9150(91)90025-X
DOI
|
14 |
Zmuda JM, Thompson PD, Dickenson R, Bausserman LL. Testosterone decreases lipoprotein (a) in men. Am J Cardiol. 1996;77:1244-1247. https://doi.org/10.1016/S0002-9149(96)00174-9
DOI
|
15 |
Harman SM, Vittinghoff E, Brinton EA, Budoff MJ, Cedars MI, Lobo RA, et al. Timing and duration of menopausal hormone treatment may affect cardiovascular outcomes. Am J Med. 2011;124:199-205. https://doi.org/10.1016/j.amjmed.2010.09.021
DOI
|
16 |
Opoku S, Gan Y, Fu W, Chen D, Addo-Yobo E, Trofimovitch D, et al. Prevalence and risk factors for dyslipidemia among adults in rural and urban china: findings from the china national stroke screening and prevention project (CNSSPP). BMC public health. 2019;19:1-15. https://doi.org/10.1186/s12889-019-7827-5
DOI
|
17 |
Wang X, Magkos F, Mittendorfer B. Sex differences in lipid and lipoprotein metabolism: it's not just about sex hormones. J Clin Endocrinol Metab. 2011;96:885-893. https://doi.org/10.1210/jc.2010-2061
DOI
|
18 |
Li S, Wu N-Q, Zhu C-G, Zhang Y, Guo Y-L, Gao Y, et al. Significance of lipoprotein (a) levels in familial hypercholesterolemia and coronary artery disease. Atherosclerosis. 2017;260:67-74. https://doi.org/10.1016/j.atherosclerosis.2017.03.021
DOI
|
19 |
Berg K. A new serum type system in man-the Lp system. Acta Pathol Microbiol Scand. 1963;59:369-382. https://doi.org/10.1111/j.1699-0463.1963.tb01808.x
DOI
|
20 |
Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the american college of cardiology/american heart association task force on clinical practice guidelines. J Am Coll Cardiol. 2019;73:e285-e350. https://doi.org/10.1016/j.jacc.2018.11.003
DOI
|
21 |
Banach M, Aronow WS, Serban C, Sahabkar A, Rysz J, Voroneanu L, et al. Lipids, blood pressure and kidney update 2014. Pharmacol Res. 2015;95:111-125. https://doi.org/10.1016/j.phrs.2015.03.009
DOI
|
22 |
Group H-TC. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014;371:203-212. https://doi.org/10.1056/NEJMoa1300955
DOI
|
23 |
Sunayama S, Daida H, Mokuno H, Miyano H, Yokoi H, Lee YJ, et al. Lack of increased coronary atherosclerotic risk due to elevated lipoprotein (a) in women≥ 55 years of age. Circulation. 1996;94:1263-1268. https://doi.org/10.1161/01.CIR.94.6.1263
DOI
|
24 |
KSoLA. Korean guidelines for the management of dyslipidemia 4th ed. 2018.
|
25 |
Papadopoulos N, Bedynek J. Serum lipoprotein patterns in patients with coronary atherosclerosis. Clin Chim Acta. 1973; 44:153-157. https://doi.org/10.1016/0009-8981(73)90375-6
DOI
|
26 |
Rader DJ, Cain W, Zech LA, Usher D, Brewer HB. Variation in lipoprotein (a) concentrations among individuals with the same apolipoprotein (a) isoform is determined by the rate of lipoprotein (a) production. J Clin Invest. 1993;91:443-447. https://doi.org/10.1172/JCI116221
DOI
|